Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Assets: 2013-2025

Historic Assets for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $516.5 million.

  • Coherus Oncology's Assets rose 2.28% to $516.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $516.5 million, marking a year-over-year increase of 2.28%. This contributed to the annual value of $448.5 million for FY2024, which is 28.76% down from last year.
  • Coherus Oncology's Assets amounted to $516.5 million in Q3 2025, which was up 17.53% from $439.5 million recorded in Q2 2025.
  • Coherus Oncology's Assets' 5-year high stood at $763.5 million during Q1 2024, with a 5-year trough of $371.1 million in Q1 2025.
  • Moreover, its 3-year median value for Assets was $505.0 million (2024), whereas its average is $527.7 million.
  • Per our database at Business Quant, Coherus Oncology's Assets skyrocketed by 89.74% in 2024 and then plummeted by 51.40% in 2025.
  • Coherus Oncology's Assets (Quarterly) stood at $679.3 million in 2021, then declined by 29.22% to $480.8 million in 2022, then soared by 30.94% to $629.6 million in 2023, then declined by 28.76% to $448.5 million in 2024, then rose by 2.28% to $516.5 million in 2025.
  • Its Assets stands at $516.5 million for Q3 2025, versus $439.5 million for Q2 2025 and $371.1 million for Q1 2025.